Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Important Notice
Ⅰ The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisors and
senior management of the Company hereby warrant the truthfulness, accuracy and completeness
of the contents of the interim report (the “Report”), and that there are no false representations,
misleading statements or material omissions contained in the Report, and severally and jointly
accept responsibility.
Ⅱ All the directors of the Company attended the Board meeting.
Ⅲ The interim report of the Company is unaudited.
Ⅳ Mr. Zhu Baoguo (朱保国), the person-in-charge of the Company, and Mr. Qiu Qingfeng (邱庆
丰), the person-in-charge of the Company's accounting work and the person-in-charge of the
accountingdepartment(theheadoftheaccountingdepartment),declarethattheyherebywarrant
the truthfulness, accuracy and completeness of the financial statements contained in the Report.
Ⅴ Profit distribution plan or plan for conversion of capital reserve to share capital approved by
the Board during the Reporting Period
Not applicable
VI Risk declaration for the forward-looking statements
√Applicable □N/A
TheReport containsforward-lookingstatements whichinvolve thefuture plans, development strategies,
etc. of the Company, yet do not constitute substantive undertakings of the Company to investors.
Investors should exercise caution prior to making investment decisions.
VII Whether there is non-operating use of funds by the controlling shareholder and their related
parties
No
VIII Whether there is a violation of the prescribed decision-making procedures to provide
external guarantees
No
IX Whether more than half of directors cannot warrant the truthfulness, accuracy and
completeness of the Report disclosed by the Company
No
X Significant risk warnings
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
There is no exceptionally significant risk that will have a material impact on the productions and
operations of the Company during the Reporting Period. The Company has described various risks
related to productions and operations that the Company may face and the corresponding response
measures taken. Please refer to “Risks” in Chapter 3 “Management Discussion and Analysis”.
XI Others
□Applicable √N/A
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Table of Contents
Financial Highlights...... 5
Chapter 1 Definitions...... 7
Chapter 2 Company Profile and Major Financial Indicators...... 9
Chapter 3 Management Discussion and Analysis ...... 13
Chapter 4 Corporate Governance ...... 49
Chapter 5 Environmental and Corporate Social Responsibility ...... 51
Chapter 6 Major Events...... 85
Chapter 7 Changes in Equity and Shareholders...... 97
Chapter 8 Information on Preferred Shares ...... 101
Chapter 9 Information on Bonds...... 102
Chapter 10 Financial statements...... 103
The Financial Statements signed and sealed by the person-in-charge of the
Company, the person-in-charge of the Company's accounting work and the
List of documents person-in-charge of the accounting department (the head of the accounting
available for inspection department)
The originalcopies of all documents and announcements of the Companywhich
have been disclosed to the public on the website designated by CSRC (China
Securities Regulatory Commission) during the Reporting Period
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Financial Highlights
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Financial Highlights
Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023
Chapter 1 Definitions
In this Report, unless the context otherwise requires, the following expressions shall have the
following meanings:
Definitions of common terms
CSRC Refers to China Securities Regulatory Commission
SSE Refers to Shanghai Stock Exchange
Baiyeyuan or the Refers to Shenzhen Baiyeyuan Investment Co., Ltd. * (深圳市百业源
Controlling Shareholder 投资有限公司)
Company or the Refers to Joincare Pharmaceutical Group Industry Co., Ltd. * (健康元
Company 药业集团股份有限公司)
GDR Refers to Global Depository Receipts
CDE Refers to Center For Drug Evaluation (国家药
查看PDF原文
